Medicare Part D coverage · dasatinib · RxCUI 643173
dasatinib 20 MG Oral Tablet [Sprycel]
Per the CMS 2026 Part D formulary file, dasatinib 20 MG Oral Tablet [Sprycel] is covered by 31 Medicare Part D plans (0.6% of enrollable products), averaging Tier 4.2, with prior authorization required on 100% of covering formularies.
- 0.6%
- Plan coverage
- 31
- Plans covering
- T4.2
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for dasatinib 20 MG Oral Tablet [Sprycel]
Per the CMS 2026 Part D formulary file, dasatinib 20 MG Oral Tablet [Sprycel] (RxNorm concept RXCUI 643173, generic name dasatinib) appears on 5 distinct formulary files spanning 31 Medicare Part D plan offerings - 0.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.2.
Real-world access to dasatinib 20 MG Oral Tablet [Sprycel] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 80% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 5,120 Part D beneficiaries filled dasatinib 20 MG Oral Tablet [Sprycel] in 2023, with total plan-and-beneficiary spending of $510,233,995 and an average per-beneficiary annual cost of $99,655.08. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry dasatinib 20 MG Oral Tablet [Sprycel] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 31
- Coverage rate
- 0.6%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 80% of formularies
2023 Medicare Spending
- Beneficiaries
- 5,120
- Total spending
- $510,233,995
- Avg per beneficiary
- $99,655.08
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering dasatinib 20 MG Oral Tablet [Sprycel]
31 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | Hamaspik, Inc. | T1 | Yes | $34.50 | NY |
| Personal Choice 65 Achieve Rx (PPO) | QCC Insurance Company | T5 | Yes | $0 | PA |
| Keystone 65 Focus Rx (HMO-POS) | Keystone Health Plan East, Inc. | T5 | Yes | $0 | PA |
| Keystone 65 Focus Rx (HMO-POS) | Keystone Health Plan East, Inc. | T5 | Yes | $0 | PA |
| Keystone 65 Basic Rx (HMO) | Keystone Health Plan East, Inc. | T5 | Yes | $0 | PA |
| AmeriHealth Medicare Core (PPO) | Amerihealth Insurance Company OF NEW Jersey | T5 | Yes | $0 | NJ |
| AmeriHealth Medicare Ultimate (PPO) | Amerihealth Insurance Company OF NEW Jersey | T5 | Yes | $0 | NJ |
| Health New England Medicare Compass (PPO) | Health NEW England, Inc. | T5 | Yes | $0 | MA |
| Health New England Medicare Value (HMO) | Health NEW England, Inc. | T5 | Yes | $0 | MA |
| Health First Rewards H1099-014 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First SunSaver H1099-016 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Complete Care H1099-023 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-024 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-025 (HMO-POS) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-026 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-027 (HMO-POS) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-028 (HMO) | Health First Health Plans | T5 | Yes | $0 | FL |
| Health First Value H1099-006 (HMO) | Health First Health Plans | T5 | Yes | $15.00 | FL |
| Health New England Medicare Premium (HMO) | Health NEW England, Inc. | T5 | Yes | $15.80 | MA |
Show the next 11 plans
| Keystone 65 Essential Rx (HMO-POS) | Keystone Health Plan East, Inc. | T5 | Yes | $31.00 | PA |
| AmeriHealth Medicare Enhanced (PPO) | Amerihealth Insurance Company OF NEW Jersey | T5 | Yes | $36.00 | NJ |
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T5 | Yes | $47.00 | PA |
| Health First Classic H1099-001 (HMO-POS) | Health First Health Plans | T5 | Yes | $49.40 | FL |
| Health New England Medicare Plus (HMO) | Health NEW England, Inc. | T5 | Yes | $58.40 | MA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T5 | Yes | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T5 | Yes | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T5 | Yes | $79.70 | PA |
| Personal Choice 65 Plus Rx (PPO) | QCC Insurance Company | T5 | Yes | $81.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T5 | Yes | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T5 | Yes | $112.70 | PA |
Frequently Asked Questions
Is dasatinib 20 MG Oral Tablet [Sprycel] covered by Medicare Part D?
Yes, dasatinib 20 MG Oral Tablet [Sprycel] is covered by 31 Medicare Part D plans (0.6% of all Part D formularies).
What tier is dasatinib 20 MG Oral Tablet [Sprycel] on Medicare Part D plans?
dasatinib 20 MG Oral Tablet [Sprycel] averages Tier 4.2 across Part D plans, ranging from Tier 1 to Tier 5.
Does dasatinib 20 MG Oral Tablet [Sprycel] require prior authorization?
100% of Part D formularies require prior authorization for dasatinib 20 MG Oral Tablet [Sprycel]. Step therapy: 0%. Quantity limits: 80%.
How much does Medicare spend on dasatinib 20 MG Oral Tablet [Sprycel]?
In 2023, total Medicare Part D spending on dasatinib 20 MG Oral Tablet [Sprycel] was $510,233,995, covering 5,120 beneficiaries. The average spend per beneficiary was $99,655.08.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- rilpivirine 2.5 MG Tablet for Oral Suspension [Edurant] T4.2
- tenofovir disoproxil fumarate 250 MG Oral Tablet [Viread] T4.2
- sodium oxybate 500 MG/ML Oral Solution T4.2
- sapropterin dihydrochloride 100 MG Oral Tablet T4.2
- ivacaftor 125 MG / lumacaftor 200 MG Oral Tablet [ORKAMBI] T4.2
- ivacaftor 125 MG / lumacaftor 100 MG Oral Granules [ORKAMBI] T4.2
Similar prior-authorization rate
- azathioprine 50 MG Oral Tablet 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B] 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- 1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- sotagliflozin 200 MG Oral Tablet [Inpefa] 100% PA
- mycophenolate mofetil 250 MG Oral Capsule 100% PA